Our people

Dr. Himanshu Gadgil brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company.

Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization.

Dr. Gadgil holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

Lata plays a critical role in shaping the organization culture, driving employee engagement and building a high performing workforce. Her extensive experience includes assignments at Cipla, Advinus Therapeutics, Allergan India Pvt. Ltd, Fresenius Kabi.

She holds a BSc. in Microbiology from Ramnarian Ruia College. She also holds a MBA in Human resource management from the SIES College of management studies, India.

Lata leads the design, implementation and execution of HR strategy, organizational design, and development for creating a global organization for Enzene. She also leads EHS efforts in fostering a culture of safety, sustainability and compliance. Additionally, in the business operation role she plays a pivotal part in enhancing the effectiveness, efficiency and impact of the CEO office by executing strategic plans, initiatives, and organizational priorities based on key data analytics and work flows.

Neel Ambani serves as the Chief Financial Officer at Enzene Biosciences, bringing over 20 years of financial leadership experience across global markets. His expertise spans strategic planning, financial control, risk management, and business transformation.

Prior to joining Enzene, Neel was the Managing Director & AVP at Eli Lilly’s Capability Center India, where he led the site’s strategic expansion and operational excellence. He also served as CFO at Elanco, overseeing financial operations for the US and EMEA regions, driving significant IBT improvement, and ensuring post-IPO compliance. Earlier in his career, he held key financial roles at Eli Lilly’s Australia and New Zealand offices, as well as its Asia Pacific Treasury operations.

Neel is a Chartered Accountant and holds an MBA from Duke University. He is passionate about building high-performing teams and leveraging financial strategy to drive business growth.

With 25+ years of strategic leadership experience in Information Technology, Kumaresan has led a wide array of initiatives in digital transformation, cybersecurity, infrastructure modernization, application development, operational excellence, and enterprise application systems.

Kumaresan holds a Master of Computer Applications from Bharathidasan University and a Diploma in Computer Science Engineering from the Tamil Nadu Technical Board. He is also certified in CISSP, PMP, and ITIL, and has been consistently recognized in the Top 100 CIO and CSO lists by IDG, along with multiple accolades from Core Media’s CIO Powerlist. Over the course of his career, Kumaresan has held senior IT leadership roles at Unichem Laboratories, DSM Sinochem Pharmaceuticals, Danisco Ingredients India Pvt. Ltd., PVR Limited, and Apex Information Services Pvt. Ltd. In these roles, he led global IT transformations, large-scale ERP implementations, and digital innovation programs that enhanced operational resilience and delivered business value.

As Head of Information Technology, Kumaresan will be focused on strengthening the digital foundation that empowers Enzene teams and will expand the capabilities that help the organization move faster, stay compliant, and deliver smarter manufacturing.

Dr. Sundar Ramanan brings over 25 years of experience across biopharmaceutical drug development to commercialization lifecycle, with strong emphasis on Quality and Regulatory compliance. His career spans both product development global companies such as Amgen, Baxter and Biocon, and CDMO Just-Evotec biologics. His notable accomplishments include FDA and EMA cGMP approval for manufacturing facilities, advancing regulatory policy with FDA leading to Phase-3 waiver for insulin and thereby enabling the 1st FDA approval for a biosimilar with interchangeability rating without Phase-3 in the US.

Dr. Ramanan is chemical Engineer by training and holds a PhD in Bioengineering from Oregon State University and an MBA from University of Michigan. He is also an accomplished speaker and author. His most recent publication is a book titled “Orphan Drug Development for Rare Disease” RAPS 2021.

As CQO, Sundar will oversee the quality unit in India and lead its expansion into the U.S. market. In India, he will manage the quality operational functions, including QA and QC, while also overseeing the centralized quality system and the quality engineering & validation units.

With over 25 years in the biopharmaceutical industry, his experience includes progressive leadership roles in Manufacturing, Validation, Quality Assurance, and Network Strategy. Norm has extensive clinical manufacturing experience with mAb and AAV processes, along with commercial experience in mAb drug substance production.

He has been part of 4 successful biopharmaceutical manufacturing facility start-ups. Prior to joining us, Norm served as the Site Head & Head of Biologics Manufacturing at PTC Therapeutics. Before that, he served as Director, Clinical Manufacturing & Business Operations at Bristol-Myers Squibb. Earlier in his career, Norm worked in manufacturing and validation roles at Centocor (J&J) and JRH Biosciences. Norm has Bachelor of Science – Biology from State University of New York – New Paltz.

Dr. Shilpa Gadgil serves as the head of process, analytical and CDMO development - leading on all project initiatives at Enzene Biosciences. Prior to Enzene, Shilpa was the Head of QC at Intas pharmaceuticals, and has lead the organization in several GMP audits from regulatory authorities such as EMA, USFDA, ANVISA, WHO, MOH, Health Canada, etc.

Shilpa holds a PhD in Biochemistry from University of Tennessee, Memphis. She has vast experience in the field of diabetes and autoimmune diseases from Universities such as UMass, UCLA etc. with over 30 publications in peer reviewed journals.

In here role, she leads end to end development from clone to drug product. She is also the lead for multiple biosimilar products being developed for the EU and US markets.

Russell is a results-oriented business development leader with over two decades of experience driving growth in the pharmaceutical and biotech industries. His expertise spans analytical services, formulation development, and manufacturing, providing him with a deep understanding of the drug development process.

Spending over a decade at Catalent Pharma Solutions, he consistently exceeded sales targets and spearheaded strategic initiatives, including the successful reinvigoration of sales in the Northeast region and the design and implementation of a global Inside Sales Group. He has also held leadership roles at Vectura, ANI Pharmaceuticals, and Scotwork, consistently demonstrating his ability to establish companies as leading CDMOs, reinvigorate sales funnels, and streamline operations.

At Enzene, Russell's focus is on forging strategic partnerships and delivering solutions that exceed expectations, driving the company's continued success.